Skip to main content
Yale Spinout Success Snapshot - Cybrexa Therapeutics
- The Chief Scientific Advisor & Scientific co-founder of Cybrexa Therapeutics is Ranjit Bindra, MD, PhD, a physician-scientist and biotech entrepreneur at the Yale School of Medicine.
- They have raised $21M in financing.
- The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, is expected to enter Phase I in 2021 in advanced solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs.